Details of the Drug Combinations

General Information of This Drug (ID: DMOQK8Z)

Drug Name

Arbidol DMOQK8Z

Synonyms

Umifenovir; Arbidole; MC-101

Indication

Disease Entry	ICD 11	Status	REF
Virus infection	1A24-1D9Z	Approved	[1]
Influenza virus infection	1E30-1E32	Phase 4	[2]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 2	[3]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

4 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Arbidol + OZ277	DCHNZ8D	OZ277	DD2 (Cell Line: DD2)	[4]
Arbidol + Idarubicin	DCQBU5W	Idarubicin	Glioblastoma? (Cell Line: T98G)	[4]
Arbidol + OZ277	DCCX1P1	OZ277	Hepatoblastoma (Cell Line: HB3)	[5]
Arbidol + Ruxolitinib	DCHHGOI	Ruxolitinib	Hodgkin lymphoma (Cell Line: L-1236)	[5]
------------------------------------------------------------------------------------

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	ClinicalTrials.gov (NCT01651663) A Study of Arbidol (Umifenovir) for Treatment and Prophylaxis of Influenza and Common Cold (ARBITR)
3	ClinicalTrials.gov (NCT04260594) Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus
4	CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966
5	CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125976